Literature DB >> 19283693

Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.

Ana S Veiga1, Leonard K Pattenden, Jordan M Fletcher, Miguel A R B Castanho, Marie Isabel Aguilar.   

Abstract

Two HIV-1 recognition domains for the human monoclonal antibodies (MAb) 2F5, which recognises the core sequence ELDKWA, and 4E10, which recognises the core sequence NWFNIT, serve as promising models for immunogens in vaccine development against HIV-1. However, the failure of these recognition domains to generate broadly reactive neutralizing antibodies, and the putative membrane-binding properties of the antibodies raised to these recognition domains, suggest that additional features or recognition motifs are required to form an efficient immunogen, which could possibly include the membrane components. In this study we used an extended peptide epitope sequence derived from the gp41 native sequence (H-NEQELLELDKWASLWNWFNITNWLWYIK-NH), which contains the two recognition domains for 2F5 and 4E10, to examine the role of model cell (POPC) and viral (POPC/cholesterol/sphingomyelin) membranes in the recognition of these two antibodies. By using a surface plasmon resonance biosensor, the binding of 2F5 and 4E10 to membranes was compared and contrasted in the presence and absence of prebound peptide epitope. The recognition of the peptide epitope by each MAb was found to be distinct; 2F5 exhibited strong and almost irreversible binding to both membranes in the presence of the peptide, but bound weakly in the absence of the peptide epitope. In contrast, 4E10 exhibited strong membrane binding in the presence or absence of the peptide epitope, and the binding was essentially irreversible in the presence of the peptide epitope. Overall, these results demonstrate that both 2F5 and 4E10 can bind to membranes prior to epitope recognition, but that high-affinity recognition of gp41-derived epitope sequences by 2F5 and 4E10 occurs in a membrane context. Moreover, 4E10 might utilise the membrane to access and bind to gp41; such membrane properties of 2F5 and 4E10 could be exploited in immunogen design.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283693     DOI: 10.1002/cbic.200800609

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  13 in total

1.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 2.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

3.  Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1.

Authors:  Ashish K Solanki; Yogendra S Rathore; Maulik D Badmalia; Reema R Dhoke; Samir K Nath; Deepak Nihalani
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

4.  Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.

Authors:  Marinieve Montero; Naveed Gulzar; Kristina-Ana Klaric; Jason E Donald; Christa Lepik; Sampson Wu; Sue Tsai; Jean-Philippe Julien; Ann J Hessell; Shixia Wang; Shan Lu; Dennis R Burton; Emil F Pai; William F Degrado; Jamie K Scott
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

5.  Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.

Authors:  Ramesh Rathinakumar; Moumita Dutta; Ping Zhu; Welkin E Johnson; Kenneth H Roux
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

6.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Authors:  Lianxing Liu; Yanling Hao; Zhenwu Luo; Yang Huang; Xintao Hu; Ying Liu; Yiming Shao
Journal:  Vaccine       Date:  2012-05-02       Impact factor: 3.641

8.  HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.

Authors:  Ji Wang; Pei Tong; Lu Lu; Leilei Zhou; Liling Xu; Shibo Jiang; Ying-hua Chen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

9.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.